According to the 2022 NCCN NSCLC treatment guidelines, the first-line therapeutic agent for NSCLC patients carrying the EGFR mutant is usually an EGFR-TKI[24], while chemotherapy remains one of the first-line pharmacological options available to date for patients with the EGFR-TKI resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.